Trident Lifeline Limited disclosed that its shareholding in subsidiary Trident Mediquip Limited has decreased to 58.23% following a private placement of equity shares to other shareholders. The reduction from the previous holding of 59.67% reflects a dilution of promoter interest in the medical device unit.

The transaction, executed on October 15, 2026, involves the allotment of shares by Trident Mediquip Limited (TML) to entities including directors and relatives of the parent company's promoters. Despite the reduced stake, Trident Lifeline retains majority control over the Surat-based subsidiary. The filing confirms the transaction was undertaken on an arm's length basis, classifying it as a related party transaction under SEBI regulations.

Subsidiary financial performance

Trident Mediquip Limited operates in the medical device industry and has shown consistent revenue growth over the last three fiscal years. The subsidiary's turnover rose from ₹20.58 crore in FY24 to ₹27.31 crore in FY26. The capital structure shows an authorized share capital of ₹11 crore and paid-up share capital of ₹10.25 crore.

Related party details and governance

The private placement involved allotments to individuals with existing ties to the parent company. Mr. Amit Bhupendra Halvawala and Mr. Chetan Chandrakant Jariwala, identified as relatives of director Rupaben Jariwala, along with Mr. Hardik Jigishkumar Desai, are part of the promoter group or board of Trident Lifeline. These individuals hold interests in Trident Mediquip, reinforcing the related-party nature of the equity infusion.

No governmental or regulatory approvals were required for this specific internal restructuring of shareholding patterns. The company stated that the primary objective was to facilitate the allotment of shares to other shareholders, thereby adjusting the ownership percentage while maintaining operational consolidation.

What the numbers show

While Trident Lifeline's stake in Trident Mediquip declined by 1.44 percentage points, the subsidiary's revenue expanded significantly during the same period. Turnover grew from ₹21.29 crore in FY25 to ₹27.31 crore in FY26, representing a substantial year-on-year increase. This divergence suggests that the dilution in ownership percentage occurred alongside strong top-line growth for the subsidiary, potentially indicating value accretion for remaining shareholders despite the lower equity share.

Trident Lifeline Limited has issued the formal notice for its Extraordinary General Meeting (EGM), scheduled for October 27, 2026, to seek shareholder approval for a ₹58 crore preferential issue. The proposal involves issuing equity shares and fully convertible warrants at ₹336.60 per unit to specific public and promoter group investors.

The board meeting on October 5, 2026, approved the issuance of 12,22,200 equity shares and up to 5,00,400 fully convertible warrants. This capital infusion is intended to meet working capital requirements, repay secured borrowings, and fund business expansion. The issue is structured under Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Details of the preferential issue

The issuance is split into two components with distinct investor categories:

1. Equity Shares: 12,22,200 shares with a face value of ₹10 each, aggregating to ₹41.14 crore. These will be issued exclusively to public category investors (non-promoters). The relevant date for price determination is September 25, 2026.
2. Equity Warrants: Up to 5,00,400 warrants, each convertible into one fully paid-up equity share. The total consideration is capped at ₹16.84 crore. These are offered to promoter/promoter group members and select non-promoter/public investors.

Investors must pay 25% of the warrant price at subscription, with the remaining 75% due upon exercise within 18 months from the date of allotment. The floor price was calculated based on the volume-weighted average price over the preceding 90 trading days on the BSE SME platform, resulting in a minimum price of ₹336.57. The final issue price of ₹336.60 includes a premium of ₹326.60 per share.

Shareholding pattern impact

Following the full conversion of warrants and allotment of shares, the shareholding pattern is expected to shift as follows:

Note: Post-issue figures assume full subscription and conversion of all warrants.

Key allottees and pricing basis

The equity share component is directed solely at non-promoter entities and individuals. Notable allottees include India Equity Fund 1 (3,04,200 shares), Motherbox Technologies Private Limited (1,48,200 shares), and Bhagwan Singh Chodhary HUF (1,03,800 shares). The warrant component sees participation from promoters, including Hardik Jigishkumar Desai and his family trust, as well as non-promoter individuals like Ashish Anandsingh Bafna.

The valuation report supporting the price was issued by Mr. Anurag Singal, a registered valuer, on October 5, 2026. The company confirmed that no change in management or control will occur as a result of this preferential issue.

Board meeting outcomes and next steps

In addition to approving the fund-raising plan, the board took several procedural steps:

• Approved the alteration of Articles of Association to include provisions for issuing warrants.
• Scheduled an Extraordinary General Meeting (EGM) for October 27, 2026, via video conferencing to seek shareholder approval.
• Appointed National Securities Depository Limited (NSDL) as the remote e-voting agency.
• Designated CS Mebul Amareliya as the scrutinizer for the e-voting process.

Remote e-voting facilities are open from October 24, 2026, to October 26, 2026. The trading window for dealing in securities remains closed effective September 29, 2026, and will reopen 48 hours after the conclusion of the board meeting.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0MKA01014/ef3d1a93-d791-4016-b21b-10e97dd9eb0c.pdf